Inflammatory bowel disease and prostate cancer risk: A systematic review

Anoud Haddad a, Mohammed Qassay Al-Sabbagh a, Hashim Al-Ani a, Abdel Muez Siyam a, Emad Aborajooh b, Takehiro Iwata c,d, Shoji Kimura c,e, Shahrokh F. Shariat b,g,h,i, and Mohammad Abufaraj a,c

aDivision of Urology, Department of Special Surgery, Jordan University Hospital, the University of Jordan, Amman, Jordan; bDepartment of Surgery, Faculty of Medicine, Muthah University, Kerak, Jordan; cDepartment of Urology, Medical University of Vienna, Vienna, Austria; dDepartment of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; eDepartment of Urology, Jikei University School of Medicine, Tokyo, Japan; fDepartment of Urology, Weill Cornell Medical College, New York, NY, USA; gDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; hKarl Landsteiner Institute of Urology and Andrology, Vienna, Austria; iInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia

ABSTRACT

Objective: To evaluate the risk of prostate cancer (PCA) in patients with inflammatory bowel disease (IBD), focussing on ulcerative colitis (UC) and Crohn’s disease (CD) separately.

Methods: A systematic search was carried out using PubMed and Web of Science databases following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We retrieved a total of 349 articles. All the articles were in the English language and investigated the incidence of PCA in patients with IBD.

Results: Nine studies met our inclusion criteria, with a total of 205,037 men. Two studies reported an increase in the risk of PCA in men with IBD in general. Five other studies reported an increased risk of PCA in men with UC or with CD specifically. On the other hand, two studies reported a decreased risk of PCA in patients with UC and patients with IBD treated with aminosalicylates.

Conclusions: While men with UC appear to have higher risk of developing PCAs, data on patients with CD are inconclusive. Therefore, patients with UC may benefit from earlier PCA screening. Our findings confirm a complex interplay between IBD and PCA, including factors such as genetic predisposition, systemic inflammation and treatment effects. The modulatory effect of treatment strategies for IBD on the development and progression of PCAs might be of clinical significance.

Abbreviations: CD: Crohn’s disease; CRP: C-reactive protein; FOLH1: folate hydrolase 1; GIT: gastrointestinal tract; IBD: inflammatory bowel disease; IL-6: interleukin 6; NOS: Newcastle–Ottawa Scale; PCA: prostate cancer; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PSMA: prostate-specific membrane antigen; UC: ulcerative colitis.

Introduction

Inflammatory bowel disease (IBD) is a chronic, idiopathic, inflammatory status of the bowel comprising two major entities: ulcerative colitis (UC) and Crohn’s Disease (CD) [1]. The highest reported prevalence of IBD is observed in Europe and North America, with an estimated incidence of 505 per 100,000 in Norway and 322 per 100,000 in Germany for UC and CD, respectively. Although the incidence of IBD is stable in highly prevalent regions, the trends have been increasing since 1990 in some newly industrialised countries in Africa and southern America, resulting in increased overall global incidence [2].

Patients with IBD are at increased risk of developing various types of cancers [3–5]. The chronic inflammatory status of the gastrointestinal tract (GIT) predisposes these patients to a higher risk of developing various GIT malignancies [3,5]. There is, additionally, increasing evidence that the body’s chronic inflammatory response and the systemic treatment of IBD increases the risk of other extra-intestinal tumours, such as skin and haematopoietic malignancies [3,4].

Several investigators have evaluated the association between IBD and urological malignancies, such as bladder cancer [3,4]. The association between IBD and the risk of developing prostate cancer (PCA) remains unclear. We hypothesised that IBD would be associated with an increased risk of developing PCAs. Therefore, we evaluated the characteristics and risks of PCAs in patients with IBD focussing on UC and CD separately.

Materials and methods

Search strategy

A systematic literature search was conducted using PubMed and Web of Science databases, on 1 October 2019. We retrieved all published articles
written in the English language that investigated the association between IBD and PCa risk. The following string terms were used: prostate cancer and ('Inflammatory bowel disease' or 'ulcerative colitis' or 'Crohn’s disease') with an overall result of 349 articles. This process was carried out by two independent reviewers who screened study titles and abstracts in order to assess and exclude irrelevant publications.

**Inclusion criteria**

Studies were only included if they reported on the prevalence/incidence of PCa in patients with IBD, or an association between IBD and PCa, only if including more than five cases of PCa.

**Quality assessment**

The quality of each individual study was assessed by two reviewers independently according to the Cochrane handbook [6]. The Newcastle–Ottawa Scale (NOS) was used to assess the quality of the included studies [7]. The scale focusses on three factors: Selection (1–4), Comparability (1–2) and Exposure (1–3). The total score ranges from 0 (lowest) to 9 (highest). The presence of confounders was determined by consensus and review of the literature.

**Data extraction**

Full-text articles were reviewed by two other reviewers independently to extract the required data based on pre-specified Excel sheets. The first author, year of publication, sample size, and the incidence of PCa in patients with IBD amongst other demographic data in all eligible studies were collected. All discrepancies regarding data extraction were resolved by consensus.

**Results**

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was adopted in conducting this systematic review (Figure 1). Our protocol was registered in the international prospective

---

**Figure 1. PRISMA flowchart.**
A register of systematic reviews database (International Prospective Register of Systematic Reviews [PROSPERO]: CRD 42,019,146,910).

After the initial search, a total of 349 studies were identified; out of which 331 studies were excluded after title and abstract assessment. An additional nine studies were excluded based on a full-text review. Finally, nine studies were included for qualitative analysis.

Characteristics of the included studies

Seven reports evaluated the incidence of various malignancies, including PCa, in patients with IBD. One study reported on the risk of developing PCa in patients with IBD and two other studies evaluated cancer risks in patients with CD and UC, respectively. Table 1 [8–16] summarises the characteristics of the included studies.

There were five retrospective studies [8–12] comprising 145,506 patients and four prospective studies [13–16] comprising 59,531 patients. Of these, two studies enrolled patients from the USA, five from Europe, and two from Asia.

Outcomes

IBD

This systematic review found that men with IBD, in general, seem to have a higher risk of developing PCa than the general population. An increased risk of PCa in men with IBD was reported in two studies [8,9]. It is worth mentioning that, Wilson et al. [15] reported a lower risk of PCa in patients with IBD treated with aminosalicylates.

UC

An increased risk of PCa in men with UC was reported in four studies [12–14,16]. One study, on the other hand, reported a lower risk of PCa in men with UC [10].

CD

Only one study reported an association between PCa and CD, where an increased risk of PCa was noted [11]. A formal meta-analysis on the risk of PCa in patients with IBD was not performed owing to the limited number of publications and the heterogeneity of the data.

Table 2 [8–16] summarises the quality assessment, selection, comparability, and outcome in each of the included studies.

Discussion

Principle findings

In the present systematic review, we aimed to investigate whether patients with IBD are at a higher risk of malignancies.
developing PCa. Overall, patients with IBD do appear to have a higher risk of developing PCa. This is especially evident in patients with UC rather than patients with CD. This association was established in six studies. One report showed an increased risk of PCa in patients with UC [11]. Two other reports appeared to have contradictory findings; Jussila et al. [10] reported that UC male patients’ risk of PCa was actually slightly less than the general population, while Wilson et al. [15] did not identify a significant association between IBD treated with aminosalicylates and PCa risk.

**Mechanisms of the association between IBD and PCa risk**

While several investigators investigated the potential association between IBD and PCa risk, the impact of IBD on disease risk remains unclear [9,11,15,16]. The postulated association can be explained by various mechanisms; however, it is complex and multifactorial.

**Genetic background**

Some authors postulated that there are mutual genetic susceptibility genes between IBD and PCa [8,17]. This finding is consistent with the fact that many autoimmune and neoplastic diseases have a common genetic background and certain genetic aberrations may confer increased risk of developing malignancies. A noteworthy example is the folate hydrolase 1 (FOLH1)/prostate-specific membrane antigen (PSMA), which appears to be upregulated in both IBD and PCa [18–21]. In fact, FOLH1/PSMA overexpression was found to be correlated with biochemical recurrence and metastasis in patients with PCa [22]. Additionally, FOLH1/PSMA inhibition resulted in tumour growth regression and size decrease in animal models [22]. Inhibiting FOLH1/PSMA also resulted in mitigation of colonic inflammation in IBD mice models [18], indicating a significant pathophysiological role for FOLH1/PSMA in both diseases.

**Inflammatory state**

In addition, the risk of PCa may be associated with IBD due to the inherent inflammatory process [23–25]; with a regional and/or systematic effect. For example, the rectum is frequently involved in IBD (common in CD, always in UC), and rectal inflammation may directly or indirectly be related to prostate pathologies, such as prostatitis. Chronic prostatitis has been suggested to eventually induce tumorigenesis within the prostate via DNA damage and oxidative stress [23–26]. Prostatitis may also be related to microbiome translocation via the inflamed bowel to the circulation, where they may ‘home’ to the prostate, among other tissues, and cause a pro-inflammatory environment [26,27]. Burns et al. [8], report higher PSA levels in older patients with IBD than their age-matched controls, which may reflect underlying prostatic inflammation and/or injury. Moreover, the inflammatory state of IBD is mediated through pro-inflammatory cytokines, including interleukin 6 (IL-6). In fact, IL-6 receptors are upregulated in PCa cells and IL-6 plays a trophic role in cancer growth [28,29]. Indeed, we and others have shown that blood levels of IL-6 and its receptor are elevated in patients with metastatic PCa [30]. Moreover, they improved the predictive accuracy of standard predictive tools in patients treated with radical prostatectomy for non-metastatic PCa [31]. C-reactive protein (CRP), an acute phase reactant that is elevated in IBD, was also associated with higher PSA levels [32–34]. In fact, higher CRP levels were found to correlate with PCa resistance to treatment and poorer survival [34,35].

**Immunosuppressive medications**

Furthermore, the use of immunosuppressive medications that control IBD may increase the risk of extra-intestinal cancers such as haematological malignancies (non-Hodgkin lymphoma) and skin cancers [36–39]. IBD immunosuppressive medications may be directly related to carcinogenesis by causing direct DNA damage, diminishing the immune surveillance over cancerous cells, or promoting chronic infections within tissues, which may induce aberrant cellular growths owing to chronic inflammatory status with associated oxidative stress [18,36,38].

**Exposure to medical personnel**

An additional possible explanation for the higher PCa detection rates in patients with IBD is their frequent exposure to medical personnel, including more clinical examinations, such as DRE before colonoscopy procedures, and the periodic investigations requested for patients with IBD [17]. Whether this is merely an over diagnosis or results in detecting clinically significant tumours needs further evaluation [40,41].

**Prostate cancer considerations**

While all included studies investigated the risk of developing PCa in the setting of IBD, none have examined the...
risk of high-risk PCa. Burns et al. [8] have concluded that IBD may be associated with an increased risk of clinically significant PCa (Grade Group ≥2). Alternatively, another report showed that patients with IBD were likely to have lower-risk PCa, but this study did not evaluate the risk of developing PCa among patients with IBD and, accordingly, was not included in the present review [42].

No clear association has been concluded about the survival outcomes in patients with PCa with IBD. Multiple studies reported serious bowel toxicities of pelvic radiation in patients with IBD [42,43]. Therefore, the restricted use of certain anti-neoplastic medications or radiotherapy may affect the overall survival of patients with PCa with IBD.

Limitations and strengths

The present review is limited by the small number and observational nature of the included studies. The heterogeneity of the currently available data precluded a formal meta-analysis to estimate the effect of IBD on the risk of PCa. Nevertheless, we shed some light into an under-studied field in the literature. Understanding the association between IBD and PCa is crucial to identify patients at higher risk of PCa. It also aids in defining new screening thresholds for patients with IBD.

Conclusion

Patients with IBD appear to have a higher risk of developing PCa, especially in patients with UC. These data support early PCa screening/early detection strategies in patients with UC. Data on the risk of PCa in patients with CD are inconclusive. Further studies are needed to elaborate on the association between IBD and PCa risk to help in patient counselling, treatment planning, and follow-up scheduling. The future holds promise to help in patient counselling, treatment planning, and follow-up scheduling. The future holds promise to

Disclosure statement

The authors report no competing conflict of interest.

ORCID

Anoud Haddad  http://orcid.org/0000-0002-9774-9004
Mohammed Qussay Al-Sabbagh  http://orcid.org/0000-0002-4872-7116
Mohammad Abufaraj  http://orcid.org/0000-0002-6603-6319

References

[1] Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun;55(6):749–53.
[2] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–2778.
[3] Axelrad JE, Lichtiger S, Vajnck V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22:4794–4801.
[4] Pedersen N, Duricova D, Elkaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480–1487.
[5] Taleban S, Elquza E, Gower-Rousseau C, et al. Cancer and inflammatory bowel disease in the elderly. Dig Liver Dis. 2016;48:1105–1111.
[6] Higgins JP, Churchill R, Chandler J, et al. editors. Cochrane handbook for systematic reviews of interventions, version 5.2.0 (updated June 2017), Cochrane. 2017. Cited Mar 2020. training.cochrane.org/handbook.
[7] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
[8] Burns JA, Weiner AB, Catalona WJ, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2019;75:846–852.
[9] Khan N, Vallarino C, Lissoos T, et al. Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients. Drugs Aging. 2017;34:859–868.
[10] Jussila A, Virta LJ, Pukkala E, et al. Malignancies in patients with inflammatory bowel disease: A nationwide register study in Finland. Scand J Gastroenterol. 2013;48:1405–1413.
[11] Hemminki K, Li X, Sundquist J, et al. Cancer risks in Crohn disease patients. Ann Oncol. 2009;20:574–580.
[12] Hemminki K, Li X, Sundquist J, et al. Cancer risks in ulcerative colitis patients. Int J Cancer. 2008;123:1417–1421.
[13] So J, Tang W, Leung WK, et al. Cancer Risk in 2621 Chinese patients with inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis. 2017;23:2061–2068.
[14] Jung YS, Han M, Park S, et al. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis. 2017;11:954–962.
[15] Wilson JC, Furlano RI, Jick SS, et al. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol. 2016;51:1050–1062.
[16] Jess T, Horváth-Puhó E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–1876.
[17] Chen M, Yuan C, Xu T. An increase in prostate cancer diagnosis during inflammatory bowel disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019. (Epub ahead of print). DOI:10.1016/j.clinre.2019.07.003
[18] Rais R, Jiang W, Zhai H, et al. FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. 2016;1:e88634.

[19] Date AA, Rais R, Babu T, et al. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease. J Control Release. 2017;263:132–138.

[20] Zhang T, Song B, Zhu W, et al. An ileal Crohn’s disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal biopsies. PLoS One. 2012;7:e37139.

[21] Yao V, Parwani A, Maier C, et al. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res. 2008;68:9070–9077.

[22] Kaittanis C, Andreou C, Hieronymus H, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med. 2018;215:159–175.

[23] Sfanos KS, Yegnasubramanian S, Nelson WG, et al. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2018;15:11–24.

[24] De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–269.

[25] Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171:536–40.

[26] Sfanos KS, Joshu CE. IBD as a risk factor for prostate cancer: what is the link? Nat Rev Urol. 2019;16:271–272.

[27] Vrakas S, Mountzouris KC, Michalopoulos G, et al. Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease. PLoS One. 2017;12:e0170034.

[28] Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986–992.

[29] Cugiz L, Puhm M. Interleukin-6 and prostate cancer: current developments and unsolved questions. Mol Cell Endocrinol. 2018;462:25–30.

[30] Shariat SF, Kattan MW, Traxel E, et al. Association of pre- and postoperative plasma levels of transforming growth factor β1 and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992–1999.

[31] Shariat SF, Karam JA, Walz J, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008;14:3785–3791.

[32] Lippi G, Montagnana M, Guidi GC. Epidemiological association between C-reactive protein and prostate specific antigen. Cancer. 2009;115:1132.

[33] Lehner S, Diamond EJ, Mamkine B, et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005;95:961–962.

[34] Beer TM, Lalani AS, Lee S, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 2008;112:2377–2383.

[35] Sevcenco S, Mathieu R, Baltzer P, et al. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis. 2016;19:163–167.

[36] Annese V, Duricova D, Gower-Rousseau C, et al. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ECCO. J Crohns Colitis. 2016;10:216–225.

[37] van den Heuvel TR, Wintjens DS, Jeuring SF, et al. Inflammatory bowel disease, cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674–688.

[38] Singh H, Canto EI, Shariat SF, et al. Improved detection of clinically significant, curable prostate cancer with systematic, 12-core biopsy. J Urol. 2004;171:1089–1092.

[39] Chun FK, Briganti A, Shariat SF, et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 2006;98:329–334.

[40] Kirk PS, Govani S, Borza T, et al. Implications of prostate cancer treatment in men with inflammatory bowel disease. Urology. 2017;104:131–136.

[41] Gestaut MM, Swanson GP. Long term clinical toxicity of radiation therapy in prostate cancer patients with inflammatory bowel disease. Rep Pract Oncol Radiother. 2017;22:77–82.